Prodia the CRO Wins Frost & Sullivan 2026 Customer Value Leadership

The award recognizes the company's dual strength in strategy effectiveness and execution. By consolidating regulatory consulting, clinical trial management, and pharmacovigilance into a single service model, Prodia the CRO minimizes vendor fragmentation for its clients. This approach has proven vital in navigating the increasingly complex regulatory requirements within Indonesia and the broader Southeast Asian market.

Central to the firm’s success is its deep-rooted connection to the Prodia Group, which provides access to the only CAP-accredited laboratory network in Indonesia. This infrastructure allows for high-quality, end-to-end data management across more than 110 active clinical studies. Beyond laboratory support, the organization has invested heavily in local research readiness, overseeing the development of 10 dedicated clinical research units and facilitating GCP certification for over 5,000 physicians.

According to Unmesh Lal, Vice President at Frost & Sullivan, the firm distinguishes itself by pairing international quality standards with granular local regulatory expertise. Erizal Sugiono, Director at PT Prodia Diacro Laboratories, noted that the company’s recent expansion into specialized pharmacovigilance services underscores a broader commitment to safety and compliance. This focus on long-term sponsor value and project transparency continues to define their competitive positioning in a rapidly evolving clinical research landscape.